Biotech Values

[bubka]

With the opportunity cost already being what it is, & any other delays would just add to that loss, am I correct in assuming that Revance is using this time to make doubly sure they won’t have an issue with the inspection? Maybe even to the point of hiring an outside expert to come in and offer advice?

Also, will we hear that the inspection is complete or is the next thing we hear is the FDA decision?